Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation

Does the novel factor XI inhibitor abelacimab reduce bleeding compared with rivaroxaban in older patients with atrial fibrillation (AF)?In this prespecified analysis of a randomized clinical trial involving 1287 patients with AF, both doses of abelacimab significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban, with a consistent relative risk reduction regardless of age. The absolute reduction in bleeding tended to be greater among older patients.Abelacimab may be a particularly attractive option for older patients with AF; however, phase 3 trial results are needed to define its efficacy and overall benefit-risk balance.

Corresponding Author: Christian T. Ruff, MD, MPH, Brigham and Women’s Hospital, 60 Fenwood Rd, Seventh Floor, Ste 7022, Boston, MA 02115 (cruff@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.